MabroukAA, EapenV.Challenges in the identification and treatment of PANDAS: a case series. J Trop Pediatr. 2009;55:46–48.
2.
SassonY, DekelS, NacaschN, . Posttraumatic obsessive-compulsive disorder: a case series. Psychiatry Res. 2005;135:145–152.
3.
de SilvaP, MarksM.The role of traumatic experiences in the genesis of obsessive-compulsive disorder. Behav Res Ther. 1999;37:941–951.
4.
HirschfeldRM, WilliamsJB, SpitzerRL, . Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry. 2000;157:1873–1875.
5.
AsmundsonGJ, FrombachI, McQuaidJ, . Dimensionality of posttraumatic stress symptoms: a confirmatory factor analysis of DSM-IV symptom clusters and other symptom models. Behav Res Ther. 2000;38:203–214.
6.
GoodmanWK, PriceLH, RasmussenSA, . The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry.1989;46:1006–1011.
7.
Zoloft [package insert].New York, NY: Pfizer;2009.
8.
MontgomerySA, McIntyreA, OsterheiderM, . A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group. Eur Neuropsychopharmacol. 1993;3:143–152.
9.
GreistJ, ChouinardG, DuBoffE, . Doubleblind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1995;52:289-295.
10.
Prozac [package insert].Indianapolis, IN: Eli Lilly and Company;2014.
11.
GershunyBS, BaerL, RadomskyAS, . Connections among symptoms of obsessive-compulsive disorder and posttraumatic stress disorder: a case series. Behav Res Ther. 2003;41:1029–1041.
